Efficacy of Flavonoid Apigenin on Hemodynamic indices, Baroreflex Function, Cardiac and Kidney Remodeling and Vasoactive-Inflammatory Biomarkers in Experimental Renal Hypertension-Reference-Cited by-同舟云学术

Efficacy of Flavonoid Apigenin on Hemodynamic indices, Baroreflex Function, Cardiac and Kidney Remodeling and Vasoactive-Inflammatory Biomarkers in Experimental Renal Hypertension

Published:2023-09-30 Issue:3 Volume:16 Page:1805-1813
ISSN:2456-2610
Container-title:Biomedical and Pharmacology Journal
language:en
Short-container-title:Biomed. Pharmacol. J.

Author:

Papiashvili N. A.¹^ORCID,Ghonghadze M. V.²^ORCID,Sharikadze N. V.³^ORCID,Khutsishvili M. P.⁴,Bakuridze K. A.¹^ORCID,Bakuridze A. J.¹^ORCID,Gongadze N. V.²^ORCID,Sukoyan G. V.⁵^ORCID

Affiliation:

1. 1Department of Pharmaceutical Technology, Tbilisi State Medical University, 33 Vazha-Pshavela ave., 0178, Tbilisi, Georgia,

2. 2Department of Medical Pharmacology, Tbilisi State Medical University, 33 Vazha-Pshavela ave., 0178, Tbilisi, Georgia.

3. 3Department of Biochemistry, Ilia State University, Kakutsa Cholokashvili Ave.3/5, 0162, Tbilisi, Georgia.

4. 4Laboratory of Biochemistry of Meta Clinic, Tamarashvili str. 4, 0162, Tbilisi, Georgia

5. 5International Scientific Center of introduction of New Biomedical Technology, Gr.Lortkipanidze str. 17e, 0137, Tbilisi, Georgia.

Abstract

The hypothesis stated here that, the long-term prevention by natural flavonoid phenolic compound, for example apigenin (Apg), improves baroreflex sensitivity and vascular resistance and occurs beneficial action for attenuation the renal hypertension (RH). One-kidney, 1-clip rats (1K1C) were treated with Apg for 2 weeks after 1 week of surgical intervention. At the end of the study in the control RH group the blood pressure (BP) increased on average by 43.5%, decreased in heart period (HP) by 9.8%, cardiochronotropic (vagal) component of baroreflex sensitivity (BRS) by 50%, and adrenergic component by 34%. Thus, in 1K1C experimental model of hypertension, provides switching to parasympathetic component and accompanied with proportionally nearly two-fold increase in epinephrine (EPN) and norepinephrine (NE) without changes in EPN/NE ratio. Morphometric changes in the kidney and heart confirmed the development of kidney and cardiac hypertrophy and renal functioning disturbances (blood urea nitrogen (BUN) increased in more than two-fold) and markers of sodium reabsorption in proximal tubule, total trans-EETs, decreased in 1.6-fold. The pronounced increased proinflammatory cytokines, interleukin 1b (IL1 b), endothelin -1 (ET-1) and tumor necrosis factor (TNF)-a confirmed the formation of “sterile inflammation” which strengthening by the nearly two-fold decreasing in the level of anti-inflammatory (vasodilatory) mediators, prostaglandin E2 (PGE2). Preventive long-term regime treatment with Apg (5mg/kg i.p./daily) in RH rats significantly decreased BP by 18.6%, increased parasympathetic component of BRS by 38.5% without marked altered its sympathetic component. Such deremodeling in BRS sensitivity associated with significant decreased in heart and kidney hypertrophy and functional activity of kidney, normalization of BUN and total EETs, reducing in circulating plasma level of catecholamines, and markedly attenuated progression of inflammation, decreased of proinflammatory levels of cytokines. Thus, Apg provides preventive beneficial pluripotent action in RH rats by exerting antihypertensive, cardio- and renoprotective effects and attenuation of “sterile inflammation”.

Publisher

Oriental Scientific Publishing Company

Subject

Pharmacology

Reference37 articles.

1. 1. Wang Z., do Carmo J.M., Aberdein N., Zhou X., Williams J.M., da Silva A.A., Hall J.E. Synergistic interaction of hypertension and diabetes in promoting kidney injury and the role of endoplasmic reticulum stress. Hypertension. 2017; 69:879–891.

2. 2. Zhou B, Carrillo-Larco R.M, Danali G, Riley L.M, Paciorek C.J, Sevens G.A, et al. Worldwide trends in Hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304):957-980.

3. 3. Alam W., Rocca C., Khan H., Hissain Y., Aschner M., DeBartolo A., Aodio N. et al. Current status and future perspectives on therapeutic potential of apigenin: focus on metabolic-dependent organ dysfunction. Antioxidants. 2021; 10:1643. hhtps://doi.org/ 10.3390/antiox10101643

4. 4. Ozawa Y., Kobori H., Suzaki Y., Navar L.G. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am. J. Physiol. Renal Physiol.2007; 292: F330–F339.

5. 5. Graham D., McBride M.W., Brain N.J., Domiczak A.F. Congenic/consomic models of hypertension. Methods Mol. Med. 2005;108:3-15.